The intervention probably leads to higher successful cannulation at the first attempt (moderate certainty).
The intervention probably leads to lower rate of complications (haematoma or ischaemia) (moderate certainty).
The intervention probably leads to higher successful cannulation within the first 2 attempts (moderate certainty).
Laparoscopic gastrectomy showed no clear difference in short‐term mortality compared with open gastrectomy (low certainty).
It is very uncertain whether laparoscopic gastrectomy changes long‐term mortality (maximal compared with open gastrectomy (very low certainty).
It is very uncertain whether laparoscopic gastrectomy changes proportion with a serious adverse event (< 3 months) compared with open gastrectomy (very low certainty).
It is very uncertain whether laparoscopic gastrectomy changes long‐term recurrence (maximal compared with open gastrectomy (very low certainty).
It is very uncertain whether laparoscopic gastrectomy changes proportion with an adverse event (< 3 months) compared with open gastrectomy (very low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).
It is very uncertain whether antithrombin changes neonatal mortality (all‐cause, < 28 days of age) compared with placebo (very low certainty).
Heparin showed no clear difference in severe IVH compared with placebo/no treatment (low certainty).
Heparin showed no clear difference in neonatal mortality (all‐cause) compared with placebo/no treatment (low certainty).